Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for IMNN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 4.189M
March 31, 2026 3.360M
December 31, 2025 7.062M
September 30, 2025 4.082M
June 30, 2025 2.660M
March 31, 2025 0.452M
December 31, 2024 4.244M
September 30, 2024 8.192M
June 30, 2024 3.741M
March 31, 2024 8.500M
December 31, 2023 13.39M
September 30, 2023 18.07M
June 30, 2023 21.52M
March 31, 2023 26.65M
December 31, 2022 29.33M
September 30, 2022 41.35M
June 30, 2022 47.04M
March 31, 2022 46.27M
December 31, 2021 55.80M
September 30, 2021 59.34M
June 30, 2021 64.05M
March 31, 2021 54.96M
December 31, 2020 18.61M
September 30, 2020 18.66M
June 30, 2020 24.21M
Date Value
March 31, 2020 16.21M
December 31, 2019 14.56M
September 30, 2019 15.46M
June 30, 2019 18.83M
March 31, 2019 21.40M
December 31, 2018 20.86M
September 30, 2018 15.13M
June 30, 2018 19.15M
March 31, 2018 23.61M
December 31, 2017 26.70M
September 30, 2017 5.287M
June 30, 2017 6.649M
March 31, 2017 6.106M
December 31, 2016 6.726M
September 30, 2016 10.57M
June 30, 2016 16.51M
March 31, 2016 15.31M
December 31, 2015 20.39M
September 30, 2015 25.08M
June 30, 2015 29.11M
March 31, 2015 26.70M
December 31, 2014 32.83M
September 30, 2014 38.92M
June 30, 2014 45.36M
March 31, 2014 40.56M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Phio Pharmaceuticals Corp. 12.60M
Agenus, Inc. -199.08M
Amgen, Inc. 11.69B
Anika Therapeutics, Inc. 137.28M
BioCryst Pharmaceuticals, Inc. -454.29M

Shareholders Equity (Quarterly) Related Metrics